![Marlene Gyldmark](https://cdn.zonebourse.com/static/resize/768/576//static/images/insiders/unknown.png)
Marlene Gyldmark
Directeur/Membre du Conseil chez International Society for Pharmacoeconomics & Outcomes Rsch
Profil
Marlene Gyldmark is currently the Director at the International Society for Pharmacoeconomics & Outcomes Research.
She has a graduate degree from York University and another graduate degree from the University of Copenhagen.
Postes actifs de Marlene Gyldmark
Sociétés | Poste | Début |
---|---|---|
International Society for Pharmacoeconomics & Outcomes Rsch
![]() International Society for Pharmacoeconomics & Outcomes Rsch Miscellaneous Commercial ServicesCommercial Services International Society for Pharmacoeconomics & Outcomes Research provides health care researches. The organization have health care researchers from all disciplines conducting health care outcomes research. These disciplines include pharmacoeconomics (health economics), epidemiology (pharmacoepidemiology), decision analysis, modeling, risk assessment, patient-reported outcomes (quality of life), use of ‘real world’ data such as health care database analyses, observational studies, patient registries. | Directeur/Membre du Conseil | - |
Formation de Marlene Gyldmark
University of Copenhagen | Graduate Degree |
York University | Graduate Degree |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
Entreprise privées | 1 |
---|---|
International Society for Pharmacoeconomics & Outcomes Rsch
![]() International Society for Pharmacoeconomics & Outcomes Rsch Miscellaneous Commercial ServicesCommercial Services International Society for Pharmacoeconomics & Outcomes Research provides health care researches. The organization have health care researchers from all disciplines conducting health care outcomes research. These disciplines include pharmacoeconomics (health economics), epidemiology (pharmacoepidemiology), decision analysis, modeling, risk assessment, patient-reported outcomes (quality of life), use of ‘real world’ data such as health care database analyses, observational studies, patient registries. | Commercial Services |